Dataset from A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-3)
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008598
下载链接
链接失效反馈官方服务：
资源简介：
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3
doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1
diabetes mellitus as adjunctive therapy to insulin
创建时间：
2025-04-28
